Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the target of a large decline in short interest in July. As of July 15th, there was short interest totaling 14,740 shares, a decline of 49.8% from the June 30th total of 29,381 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average daily volume of 2,478,882 shares, the days-to-cover ratio is currently 0.0 days.

Hedge Funds Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 70.55% of the company’s stock.

Ernexa Therapeutics Stock Up 0.1%

ERNA stock traded up $0.01 during midday trading on Thursday, hitting $3.42. The company’s stock had a trading volume of 17,996 shares, compared to its average volume of 931,105. The stock has a market cap of $4.00 million, a price-to-earnings ratio of -0.13 and a beta of 2.50. The stock’s 50-day moving average price is $6.96 and its 200 day moving average price is $10.04. Ernexa Therapeutics has a 1 year low of $3.18 and a 1 year high of $71.50.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($6.95) EPS for the quarter, missing the consensus estimate of ($1.95) by ($5.00). As a group, equities analysts forecast that Ernexa Therapeutics will post -18.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ERNA. Wall Street Zen raised shares of Ernexa Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Brookline Capital Markets started coverage on shares of Ernexa Therapeutics in a report on Thursday, May 7th. They issued a “buy” rating and a $30.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Friday, July 17th. Finally, Zacks Research raised Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $30.00.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.